High‑Cost, High‑Benefit: A New Look at MS Drugs in Brazil
A large Brazilian health insurer recently ran a study to see how expensive but powerful medicines for multiple sclerosis (MS) stack up against one another. The goal was to find out which drugs give the best value for money when they are used by many patients. Instead of simply listing prices, the